Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients
WAKEFIELD, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical…
WAKEFIELD, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical…
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:…
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) — Arch Biopartners Inc. (“Arch” or the “Company”) (TSX…
Revenues of Operating Division Increase by 50.4% NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) —…
– Calls to unite global communities affected by rare diseases – – Albireo supports increasing…
Agreement includes COVID-19 vaccine technology transfer to Takeda for local manufacturing and commercialization in Japan…
SOUTH JORDAN, Utah, Feb. 26, 2021 (GLOBE NEWSWIRE) — Health Catalyst, Inc. (“Health Catalyst”, Nasdaq:…
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a clinical-stage company focused…
FY’20 Total Revenue of $673.3 Million, +7.5% vs. FY’19 FY’20 Net Income of $70.1 Million,…
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) — Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an…